secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001213900-23-039032
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Q1 net loss $2.9M; cash $2.3M; sells Purnovate for up to $83M milestones
------------------------------------------------------------------------------

- Q1 2023 net loss $2.9 million, flat YoY; cash $2.3M vs $4.0M at Dec 2022.
- Sold Purnovate assets to Adovate for $0.45M upfront + up to $83M milestones + 19.9% equity stake.
- Engaged The Keswick Group for partnering; awaiting regulatory meeting minutes from FDA, EMA agencies.
- Closed ATM offering of 1.83M shares at $0.41 for gross $750K.
- Cash runway expected into Q1 2024, helped by non-dilutive Purnovate sale proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023039032/0001213900-23-039032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023039032/ea178472-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-039032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer